Factors associated with obstetrician-gynecologists' response to the women's health initiative trial of combined hormone therapy

Medical Decision Making

Volumn 28, Issue 3, 2008, Pages 411-418

  Power, Michael L ^a   Baron, Jonathan ^b   Schulkin, Jay ^a  

^a AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hormone therapy; Obstetrician gynecologists; Women's Health Initiative

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; AWARENESS; CLINICAL PRACTICE; CONTROLLED STUDY; DECISION MAKING; FEMALE; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; MALE; MEDICAL PROFESSION; MEDICAL RESEARCH; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; PHYSICIAN; QUESTIONNAIRE; WOMEN'S HEALTH;

ADULT; ATTITUDE OF HEALTH PERSONNEL; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; FEMALE; GYNECOLOGY; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MIDDLE AGED; OBSTETRICS; PHYSICIANS; QUESTIONNAIRES; WOMEN'S HEALTH;

EID: 44049101568     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X07312722     Document Type: Article

References (16)

1. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas (TX): American Heart Association.
2. Grodstein F., Stampfer MJ The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995 ; 38: 199-210.
3. Grodstein F., Stampfer MJ Estrogen for women at varying risk of coronary disease. Maturitas. 1998 ; 30: 19-26.
4. Hu FB, Grodstein F. Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiological evidence. Am J Cardiol. 2002 ; 90: 26F.
5. Mendelsohn ME, Karas RH The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999 ; 340: 1801-11.
6. Ahkrass F., Evans AT, Wang Y., et al. Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J Clin Endocrinol Metab. 2003 ; 88: 5611-4.
7. Humphrey LL, Chan BKS, Sox HC Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002 ; 137: 273-84.
8. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002 ; 288: 321-33.
9. Peterson M. Survey halted, drug makers seek to protect hormone sales. New York Times 17 July 2002: C1.
10. Hersh AL, Stefanick ML, Stafford RS National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004 ; 291 (1). 47-53.
11. Majumdar SR, Almasi EA, Stafford RS Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA. 2004 ; 292 (16). 1983-8.
12. Power ML, Zinberg S., Schulkin J. A survey of obstetrician-gynecologists concerning practice patterns and attitudes towards hormone therapy. Menopause. 2006 ; 13: 434-41.
13. Power ML, Schulkin J., Rossouw JE The evolving practice patterns and attitudes towards hormone therapy of obstetrician-gynecologists. Menopause. 2007 ; 14: 20-8.
14. Aberegg SK, Haponick EF, Terry PB Omission bias and decision making in pulmonary and critical care medicine. Chest. 2005 ; 128: 1497-505.
15. Baron J., Holzman GB, Schulkin J. Attitudes of obstetricians and gynecologists toward hormone replacement therapy. Med Decis Making. 1998 ; 18: 406-11.
16. Power ML, Schulkin J. Obstetrician-gynecologists' patients' knowledge of and attitudes towards hormone therapy: a survey. J Reprod Med. 2006 ; 51: 525-34.